Scholarlink

Background <p>For patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus doublet chemotherapy. However, the differences in outcomes between cetuximab and panitumumab remain unknown.</p> Methods <p>Clinical data of patients with left-sided all <i>RAS</i> or <i>KRAS</i> wild-type mCRC who received cetuximab or panitumumab plus doublet chemotherapy were retrospectively collected from 24 institutions in Japan. The patients were divided into two groups: the cetuximab and panitumumab groups. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were compared between the two groups.</p> Results <p>A total of 233 patients were enrolled: 87 (37.3%) in the cetuximab group and 146 (62.7%) in the panitumumab group. Median OS, PFS, and RR of the cetuximab and panitumumab groups were 26.6&#xa0;months (95% confidence interval [CI], 19.7–33.4) versus 31.8&#xa0;months (95% CI, 25.7–37.9), 9.7&#xa0;months (95% CI, 6.9–12.5) versus 12.4&#xa0;months (11.1–13.7), and 57.8% versus 71.0%, respectively. In multivariate analysis, OS and RR were significantly better in the panitumumab group than in the cetuximab group (adjusted hazard ratio 0.69, 95% CI 0.50–0.99, <i>p</i> = 0.04; adjusted odds ratio 2.00, 95% CI 1.07–3.73, <i>p</i> = 0.03) and PFS was similar between the two groups (adjusted hazard ratio 0.75, 95% CI 0.55–1.01, <i>p</i> = 0.05).</p> Conclusion <p>As a first-line treatment for patients with left-sided all <i>RAS</i> or <i>KRAS</i> wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

  • 期刊论文

  • 发表日期：

    2026年3月4日

查看全文
  • Ryosuke Kawagoe,
  • Toshikazu Moriwaki,
  • Kentaro Yamazaki,
  • Hiroki Yukami,
  • Hiroyuki Uetake,
  • Masahiro Tsuda,
  • Takeshi Suto,
  • Naotoshi Sugimoto,
  • Hitoshi Ojima,
  • Yasumasa Takii,
  • Hisateru Yasui,
  • Masato Komoda,
  • Yasuhiro Shimada,
  • Akihito Tsuji,
  • Toshifumi Yamaguchi,
  • Ryoichi Sawada,
  • Katsunori Shinozaki,
  • Satoshi Otsu,
  • Kunitoshi Shigeyasu,
  • Kenji Tsuchihashi,
  • Takao Tamura,
  • Manabu Shiozawa,
  • Hideki Ueno,
  • Tadamichi Denda,
  • Takahiko Ito,
  • Atsuo Takashima

摘要

Background

For patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus doublet chemotherapy. However, the differences in outcomes between cetuximab and panitumumab remain unknown.

Methods

Clinical data of patients with left-sided all RAS or KRAS wild-type mCRC who received cetuximab or panitumumab plus doublet chemotherapy were retrospectively collected from 24 institutions in Japan. The patients were divided into two groups: the cetuximab and panitumumab groups. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were compared between the two groups.

Results

A total of 233 patients were enrolled: 87 (37.3%) in the cetuximab group and 146 (62.7%) in the panitumumab group. Median OS, PFS, and RR of the cetuximab and panitumumab groups were 26.6 months (95% confidence interval [CI], 19.7–33.4) versus 31.8 months (95% CI, 25.7–37.9), 9.7 months (95% CI, 6.9–12.5) versus 12.4 months (11.1–13.7), and 57.8% versus 71.0%, respectively. In multivariate analysis, OS and RR were significantly better in the panitumumab group than in the cetuximab group (adjusted hazard ratio 0.69, 95% CI 0.50–0.99, p = 0.04; adjusted odds ratio 2.00, 95% CI 1.07–3.73, p = 0.03) and PFS was similar between the two groups (adjusted hazard ratio 0.75, 95% CI 0.55–1.01, p = 0.05).

Conclusion

As a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.